Chondroitin/Glucosamine Osteoarthritis Risk Reduction Claim Requested
This article was originally published in The Tan Sheet
Executive Summary
Weider Nutrition International seeks FDA approval for claims that products containing glucosamine and/or chondroitin sulfate "may reduce the risk of osteoarthritis," according to a health claim petition filed by the firm
You may also be interested in...
Food advisory committee meeting
Proposed osteoarthritis health claims for glucosamine & chondroitin sulfate, as well as crystalline glucosamine sulfate are the topic of the next meeting of CFSAN's Food Advisory Committee, scheduled for June 7 and 8. A portion of the meeting involving the Dietary Supplement Subcommittee will gather information and advice related to the etiology of osteoarthritis and the relevance of scientific studies cited in the petitions. The meeting will be held at the Bethesda Marriott, 5150 Pooks Hill Road. Weider filed a petition with FDA in mid-2003 seeking a qualified health claim to link products containing glucosamine and/or chondroitin sulfate with a reduced risk of osetoarthritis (1"The Tan Sheet" June 16, 2003, p. 17)...
Food advisory committee meeting
Proposed osteoarthritis health claims for glucosamine & chondroitin sulfate, as well as crystalline glucosamine sulfate are the topic of the next meeting of CFSAN's Food Advisory Committee, scheduled for June 7 and 8. A portion of the meeting involving the Dietary Supplement Subcommittee will gather information and advice related to the etiology of osteoarthritis and the relevance of scientific studies cited in the petitions. The meeting will be held at the Bethesda Marriott, 5150 Pooks Hill Road. Weider filed a petition with FDA in mid-2003 seeking a qualified health claim to link products containing glucosamine and/or chondroitin sulfate with a reduced risk of osetoarthritis (1"The Tan Sheet" June 16, 2003, p. 17)...
Food advisory committee meeting
Proposed osteoarthritis health claims for glucosamine & chondroitin sulfate, as well as crystalline glucosamine sulfate are the topic of the next meeting of CFSAN's Food Advisory Committee, scheduled for June 7 and 8. A portion of the meeting involving the Dietary Supplement Subcommittee will gather information and advice related to the etiology of osteoarthritis and the relevance of scientific studies cited in the petitions. The meeting will be held at the Bethesda Marriott, 5150 Pooks Hill Road. Weider filed a petition with FDA in mid-2003 seeking a qualified health claim to link products containing glucosamine and/or chondroitin sulfate with a reduced risk of osetoarthritis (1"The Tan Sheet" June 16, 2003, p. 17)...